|Bid||8.06 x 900|
|Ask||8.21 x 3100|
|Day's Range||7.70 - 8.25|
|52 Week Range||4.71 - 19.47|
|Beta (5Y Monthly)||1.07|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jun 29, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||38.75|
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today highlighted its presence at the 2021 Transplantation & Cellular Therapy (TCT) Annual Meeting, which is being held virtually from February 8th – 12th. The TCT meeting organizes thousands of transplant professionals from over five hundred transplant centers worldwide and is a seminal event for Actinium given its focus on targeted conditioning for bone marrow transplant (BMT), CAR-T and other adoptive cell therapies and gene therapy. At TCT, Actinium's pivotal Phase 3 trial SIERRA trial for Iomab-B was featured in 2 oral presentations, as well as CME event focused on AML and BMT and in investigator interactions led by Actinium's clinical development and medical affairs teams.
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that management will participate in the BIO CEO & Investor conference, which is being held digitally February 16 – 18, 2021.
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that members of its executive team will participate in a fireside chat at the B. Riley Oncology Investor Conference, which is being held virtually from January 20th to 21st. During the event, Sandesh Seth, Actinium's Chairman and CEO, Dr. Mark Berger, Chief Medical Officer, and Dr. Dale Ludwig, Chief Scientific and Technology Officer will participate in a fireside chat discussion moderated by B. Riley analyst Justin Walsh.